ID   HG2L6.1c3
AC   CVCL_DC31
DR   cancercelllines; CVCL_DC31
DR   Wikidata; Q54885926
RX   PubMed=21394221;
CC   Population: Caucasian.
CC   Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay. CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists.
CC   Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 16
//
RX   PubMed=21394221; DOI=10.1007/s11426-010-0142-8;
RA   Zhao B., Baston D.S., Khan E., Sorrentino C., Denison M.S.;
RT   "Enhancing the response of CALUX and CAFLUX cell bioassays for
RT   quantitative detection of dioxin-like compounds.";
RL   Sci. China Chem. 53:1010-1016(2010).
//